Dr. Elias Jabbour, MD
Claim this profileM D Anderson Cancer Center
Expert in T-Lymphoblastic Leukemia/Lymphoma
Expert in Acute Lymphoblastic Leukemia
20 reported clinical trials
31 drugs studied
About Elias Jabbour, MD
Education:
- Obtained MD from Saint Joseph University School of Medicine, Beirut, Lebanon, in 1998.
- Earned a Master's degree in Biological Sciences from Saint Joseph University, Beirut, Lebanon, in 1999.
- Completed a Clinical fellowship in Hematology-Oncology at the Gustave Roussy Institute, Villejuif, France, in 2001.
- Holds additional diplomas in Clinical Carcinology and Hematology from University of Paris XI and V School of Medicine, Paris, France, in 2002 and 2003, respectively.
Experience:
- Completed Residency at Saint Joseph’s School of Medicine and Hotel Dieu de France University Hospital, Lebanon.
- Undertook a Fellowship in Hematology/Leukemia and Stem Cell Transplantation at the University of Texas MD Anderson Cancer Center, Houston, TX, from 2003 to 2007.
- Has been a faculty member in the Leukemia Department at MD Anderson Cancer Center since 2007, achieving the rank of Professor in 2013.
- Currently serves as the Chief of the Acute Lymphocytic Leukemia section in the Department of Leukemia at MD Anderson Cancer Center.
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderPhiladelphia chromosome positive
BCR-ABL positive
BCR-ABL1 positive
2Acute Lymphoblastic Leukemia
Global LeaderPhiladelphia chromosome positive
BCR-ABL1 positive
t(9;22) positive
Affiliated Hospitals
Clinical Trials Elias Jabbour, MD is currently running
Asciminib
for Chronic Myelogenous Leukemia
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Recruiting1 award Phase 2
Combination Chemotherapy + Immunotherapy
for Acute Lymphoblastic Leukemia
This phase II trial studies how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome (Ph)-positive, or BCR-ABL positive, or acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ponatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab, methotrexate, cytarabine, and ponatinib may work better in treating patients with acute lymphoblastic leukemia.
Recruiting1 award Phase 2
More about Elias Jabbour, MD
Clinical Trial Related1 year of experience running clinical trials · Led 20 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Elias Jabbour, MD has experience with
- Blinatumomab
- Cyclophosphamide
- Rituximab
- Methotrexate
- Cytarabine
- Inotuzumab Ozogamicin
Breakdown of trials Elias Jabbour, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Lymphoblastic Leukemia
Lymphoid Leukemia
Chronic Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elias Jabbour, MD specialize in?
Elias Jabbour, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Lymphoblastic Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL positive.
Is Elias Jabbour, MD currently recruiting for clinical trials?
Yes, Elias Jabbour, MD is currently recruiting for 10 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Elias Jabbour, MD has studied deeply?
Yes, Elias Jabbour, MD has studied treatments such as Blinatumomab, Cyclophosphamide, Rituximab.
What is the best way to schedule an appointment with Elias Jabbour, MD?
Apply for one of the trials that Elias Jabbour, MD is conducting.
What is the office address of Elias Jabbour, MD?
The office of Elias Jabbour, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.